CytoSorbents (CytoSorbents) ROCE % : -100.55% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CytoSorbents's annualized ROCE % for the quarter that ended in Dec. 2023 was -100.55%.

CytoSorbents ROCE % Historical Data

The historical data trend for CytoSorbents's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents ROCE % Chart

CytoSorbents Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-86.41

-21.33

-29.23

-48.74

-67.67

CytoSorbents Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-48.12	-62.79	-58.88	-75.68	-100.55

CytoSorbents ROCE % Calculation

CytoSorbents's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-31.209	/	( ( (63.232 - 9.715)	+	(53.261 - 14.546) )	/ 2 )
	=	-31.209	/	( (53.517	+	38.715)	/ 2 )
	=	-31.209	/	46.116
	=	-67.67 %

CytoSorbents's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-37.364	/	( ( (47.575 - 11.972)	+	(53.261 - 14.546) )	/ 2 )
	=	-37.364	/	( ( 35.603	+	38.715 )	/ 2 )
	=	-37.364	/	37.159
	=	-100.55 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

CytoSorbents (NAS:CTSO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CytoSorbents ROCE % Related Terms

Thank you for viewing the detailed overview of CytoSorbents's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoSorbents (CytoSorbents) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HQE1:Germany

Address

305 College Road East, Princeton, NJ, USA, 08540

Website

https://www.cytosorbents.com

CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

Executives

Edward Raymond Jones	director	70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch	officer: Chief Financial Officer	3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi	officer: Chief Operating Officer	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan	director, officer: President and CEO	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris	officer: Chief Medical Officer	C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim	director	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel	director	293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator	director	C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico	officer: Chief Financial Officer	10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus	director	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen	officer: Chief Medical Officer	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp	10 percent owner	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley	10 percent owner	9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger	officer: See Remarks	7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino	officer: Chief Financial Officer	C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852